Total

Non-survivor

Survivor

n

30

13

17

p < 0.05

Age (x ± s)

55.5

± 18.3

68

58.2-74.5

40

34-57

0.043

Women (%)

16

53.30%

7

61.50%

9

47.10%

1.00

Comorbidities (≥ 2)

5

16.70%

2

15.40%

3

17.60%

1.00

Global hospital stay^∞

35.5

20-6008

29

15.5-39

13

17-Aug

0.563

Hospital stay previous to the diagnosis and treatment initiation^∞

16.5

8.5-29.8

23.5

11.5-38.3

10

17-May

0.205

HScore^∞

270.5

248.2-302.5

268

251-289

274

240-304

1.00

Splenomegaly

16

53.30%

7

53.80%

9

52.90%

1.00

Hepatomegaly

10

33.30%

5

38.50%

5

29.40%

0.705

Hb (g/dL)

7.1

6.4-7.9

7.1

6.2-7.8

7.1

6.6-7.8

0.094

Pt (x10⁹/L)

13500

5000-52500

16000

11000-44000

12 000

5000-99000

0.281

Pt ≤ 100 000

25

83.30%

13

100%

12

70.60%

0.052

Leu (x10⁹/L)

1250

238-353

1300

150-3940

1400

200-3340

0.457

Neu (x10⁹/L)

615

0-1550

1290

20-3 300

650

0-1400

0.805

Fb (mg/dL) (n = 24)

171

111-358

167

106-253

169

103-451

0.796

Fer (ng/mL) (n = 28)

15330

5 434-38284

29063

5728-74604

13225

8287-28729

0.108

Tg (mmol/L)

341

226-438

254

184-382

471

341-604

0.053

Tg ≥ 160 mg/dl

25

83.30%

10

76.90%

15

88.20%

0.63

AST (U/L)

139

78-406

133

101-513

179

101-512.5

0.483

ALT (U/L)

162

46-389

109

41-333

199

99-298

0.198

LDH (U/L)

737

521-1 126

956

602-1 282

845

564-1 932

0.363

T.B. (mg/dL)

2.1

1-11.2

3.4

1.4-17.8

2.5

1.1-12.4

0.145

INR (n = 29)

1.5

1.1-1.9

2.1

1.2-3.7

1.5

1.1-1.6

0.028

T.P. (n = 29)

4.8

± 1.04

4.7

3.9-4.9

4.6

4.3-5.6

0.199

A.P.

234

121-413

204

144-481

388

104-491

0.869

GGT

233

110-548

239

120-427

491

119-681

0.902